Day: March 30, 2022

The Company also Plans on Sharing INKmune™ Patient Case Studies Boca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce the Company’s Chief Scientific Officer Dr. Lowdell will be leading a workshop on the role of natural killer (NK) cells in the treatment of solid tumors. The presentation, titled, “Challenges of NK Immunotherapy of Solid Tumors: Potentiation of intra-tumoral NK Function,” is part of the 7th Innate Killer Summit being held in San Diego from March 30 to April 1. The Innate Killer Summit conference is widely viewed as one of the most important meetings in translational NK cell immunotherapy. “NK cells...

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) — Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced today that it will present preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Presentation Details: Title: Dose Range Finding Study in Non-human Primates Confirms the Unique Mechanism of Action of CTX-8371, a Novel Bispecific Antibody Blocking PD-1 and PD-L1 Abstract Number: 5027 Session Title: Combination Immunotherapies / Therapeutic Antibodies Presenter:...

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled “Novel Approaches Tackling Autoimmune Conditions” at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6th 2022. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities...

ORANGE, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, marked one year of being publicly listed. With the popular growth of Medicare Advantage, Alignment is emerging as an innovator, continuing to scale its care delivery model with its proprietary AVA® technology, programs tailored to members’ needs and value of treating every member like family. Alignment’s first trading day was March 26, 2021. “Over the past year, we’ve continued to set ourselves apart with our proven ability to improve care while lowering costs,” said John Kao, founder and CEO, Alignment Healthcare. “We’ve grown into new markets and deliver products that are responsive and highly relevant to the changing needs of our seniors. We continued to invest in innovative platforms that scale our...

WILMINGTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) (the “Company,” “UniFirst” or “we”) today reported results for its second quarter ended February 26, 2022 as compared to the corresponding period in the prior fiscal year: Q2 2022 Financial HighlightsConsolidated revenues for the second quarter increased 8.2% to $486.7 million. Operating income was $22.6 million, a decrease of 44.4%. The quarterly tax rate decreased to 19.0% compared to 22.7% in the prior year. Net income decreased to $18.5 million, or 43.4%. Diluted earnings per share decreased to $0.97 from $1.71 in the prior year, or 43.3%.The Company’s financial results for the second quarter of fiscal 2022 included $6.7 million of costs directly attributable to its CRM, ERP and branding initiatives (the “Key Initiatives”). Excluding these...

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibiting inflammation in arthritic joints of mice Data supports potential broad utility of VYN201 as a potent anti-inflammatory molecule delivered across multiple dosage formsBRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive preclinical data in a rheumatoid arthritis (“RA”) model from its VYN201 program. The data...

All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 months 73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration compared to pre-study situation Encouraging preliminary Overall Survival (OS) at the 6-month landmark, with a 73% survival rate 5.6% of patients (2/36) had confirmed and durable partial responses, with both patients continuing in the trial for over 9 months and 23 months, well beyond expectations Efti continues to be safe and well toleratedSYDNEY, AUSTRALIA, March 30, 2022 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),...

FOND DU LAC, Wisc., March 30, 2022 (GLOBE NEWSWIRE) — Mercury Marine, a division of Brunswick Corporation (NYSE: BC), continues to expand its presence and grow market share at key saltwater boat shows.  During the Palm Beach International Boat Show this past weekend, Mercury captured close to 60% share of total outboard engines at the show and almost 70% share of all outboard engines over 200hp on the water. This marks the largest share of outboard engines for Mercury at a Florida show and continues its share gains during key Florida boat shows including Miami and Ft. Lauderdale. “The Palm Beach Boat Show is quickly becoming one of the most important saltwater shows in the United States and Mercury’s outstanding performance at the show underscores our continued growth in the saltwater market,” said Chris Drees, Mercury Marine president....

VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce that BRS Inc. (“BRS”) has completed a mineral resource estimate for four of the nine uranium and vanadium properties – known as JD-6, JD-7, JD-8 and JD-9 – contained within its 100% owned West Slope project (“West Slope”) located in the prolific Uravan region of Colorado.An Indicated Mineral Resource of 1,367,000 tons of mineralized material with an average grade of 0.197% eU3O8 (equivalent to an Indicated Resource of 5,381,000 pounds of eU3O8); An Inferred Mineral Resource of 1,367,000 tons of mineralized material with an average grade of 0.984% V2O5 (equivalent to an Inferred Resource of 26,906,000 pounds of V2O5);The resources above are shown at...

Highlights:10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect recommendation to proceed – cohort five recruitment underwaySYDNEY, Australia, March 30, 2022 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing new classes of synthetic anti-infectives, is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects. “Achieving a dosing level of 1,000mg is another significant milestone for the Company,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Indicating R327...